Evidence map›Paper›PMID 37992546›Full record

ArticleNeurobiology of aging2024

A genetic and transcriptomic assessment of the KTN1 gene in Parkinson's disease risk.

Anni Moore, Peter Wild Crea, Mary Makarious, Sara Bandres-Ciga, Cornelis Blauwendraat, Monica Diez-Fairen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Anni MooreComputational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA.
Peter Wild CreaMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA.
Mary MakariousMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA; UCL Movement Disorders Centre, University College London, 33 Queen Square, 6th floor, WC1N 3BG Box 146, London, UK.
Sara Bandres-CigaMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA; Center for Alzheimer's and Related Dementias, National Institute on Aging, 9000 Rockville Pike, Building T44, Bethesda, MD 20892, USA. Electronic address: sara.bandresciga@nih.gov.
Cornelis BlauwendraatMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA; Center for Alzheimer's and Related Dementias, National Institute on Aging, 9000 Rockville Pike, Building T44, Bethesda, MD 20892, USA.
Monica Diez-FairenMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Building 35, Bethesda, MD 20892, USA.
National Institutes of Health · US

Funding

NINDS Biomarker RepositoryU24NS095871 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI TATIANA M. FOROUD · 2015 to 2026
$18.3M
Genetic characterization of atypical parkinsonismZIANS003154 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SCHOLZ, SONJA · 2016 to 2025
$15.4M
Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
MIDCAREER AWARD IN PATIENT ORIENTED RESEARCH ON AGINGK24AG000949 · NIA · YALE UNIVERSITY · PI INOUYE, SHARON K. · 1999 to 2009
$1.4M
Prospective studies on Parkinson's diseaseZ01ES101986 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CHEN, HONGLEI · 2006 to 2008
$1.2M
Department of Defense W81XWH-09–2-0128Intramural NIH HHS Z01 AG000949Intramural NIH HHS Z01 ES101986Intramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA NS003154NIA NIH HHS K24 AG000949NIA NIH HHS Z01- AG000949–02NINDS NIH HHS U24 NS095871
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurological disorder caused by both genetic and environmental factors. An association has been described between KTN1 genetic variants and changes in its expression in the putamen and substantia nigra brain regions and an increased risk for PD. Here, we examine the link between PD susceptibility and KTN1 using individual-level genotyping data and summary statistics from the most recent genome-wide association studies (GWAS) for PD risk and age at onset from the International Parkinson's Disease Genomics Consortium (IPDGC), as well as whole-genome sequencing data from the Accelerating Medicines Partnership Parkinson's disease (AMP-PD) initiative. To investigate the potential effect of changes in KTN1 expression on PD compared to unaffected individuals, we further assess publicly available expression quantitative trait loci (eQTL) results from GTEx v8 and BRAINEAC and transcriptomics data from AMP-PD. Overall, we found no genetic associations between KTN1 and PD in our cohorts but found potential evidence of differences in mRNA expression, which needs to be further explored.

Indexed as

Membrane ProteinsParkinson DiseaseCohort StudiesGenetic VariationHumansMiddle AgedPars CompactaPutamenRNA, MessengerTranscriptomeKTN1 protein, humanMembrane ProteinsRNA, MessengerGWASKTN1Parkinson’s diseasePutamenRisk factorSubstantia nigraWGS

Identifiers

PMID37992546
PMCPMC10843739
OpenAlexW4388573486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.